Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody
Cardiovascular Research · 2024
DOI: 10.1093/cvr/cvae146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Isabell Singerer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Fibronectins, Mice, Knockout, Disease Models, Animal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Aims
Pulmonary vascular and right ventricular (RV) remodelling processes are important for development and progression of pulmonary hypertension (PH). The current study analysed the functional role of the extra domain A-containing fibronectin (ED-A+ Fn) for the development of PH by comparing ED-A+ Fn knockout (KO) and wild-type (WT) mice as well as the effects of an antibody-based therapeutic approach in a model of monocrotaline (MCT)-induced PH, which will be validated in a model of Sugen 5416/hypoxia-induced PH. Methods and results PH was induced using MCT (PH mice). Sixty-nine mice were divided into the following groups: sham-treated controls (WT: n = 7; KO: n = 7), PH mice without specific treatment (WT: n = 12; KO: n = 10), PH mice treated with a dual endothelin receptor antagonist (macitentan; WT: n = 6; KO: n = 11), WT PH mice treated with the F8 antibody, specifically recognizing ED-A+ Fn, (n = 8), and WT PH mice treated with an antibody of irrelevant antigen specificity (KSF, n = 8). Compared to controls, WT_PH mice showed a significant elevation of the RV systolic pressure (P = 0.04) and RV functional impairment including increased basal RV (P = 0.016) diameter or tricuspid annular plane systolic excursion (P = 0.008). In contrast, KO PH did not show such effects compared to controls (P = n.s.). In WT_PH mice treated with F8, haemodynamic and echocardiographic parameters were significantly improved compared to untreated WT_PH mice or those treated with the KSF antibody (P < 0.05). On the microscopic level, KO_PH mice showed significantly less tissue damage compared to the WT_PH mice (P = 0.008). Furthermore, lung tissue damage could significantly be reduced after F8 treatment (P = 0.04). Additionally, these findings could be verified in the Sugen 5416/hypoxia mouse model, in which F8 significantly improved echocardiographic, haemodynamic, and histologic parameters.
Conclusion
ED-A+ Fn is of crucial importance for PH pathogenesis representing a promising therapeutic target in PH. We here show a novel therapeutic approach using antibody-mediated functional blockade of ED-A+ Fn capable of attenuating and partially reversing PH-associated tissue remodelling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.
- Department of Cardiology, Angiology and Intensive Care Medicine, Cardiovascular Center Rotenburg, Klinikum Hersfeld-Rotenburg, Heinz-Meise-Str. 100, 36199 Rotenburg an der Fulda, Germany.
- Philochem AG, Otelfingen, Switzerland.
- Department of Cardiothoracic Surgery, University Hospital Jena, Jena, Germany.
- Center for Molecular Biomedicine, Institute of Molecular Cell Biology, University Hospital Jena, Jena, Germany.
- Section Pathology, Institute of Legal Medicine, University Hospital Jena, Jena, Germany.
Zitieren
APA
Singerer, I., Tempel, L., Gruen, K., Heiß, J., Gutte, C., Matasci, M., Schrepper, A., Bauer, R., Berndt, A., Jung, C., Schulze, P. C., Neri, D., & Franz, M. (2024). Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae146
Vancouver
Singerer I, Tempel L, Gruen K, Heiß J, Gutte C, Matasci M, et al. Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae146
BibTeX
@article{Singerer2024,
author = {Singerer, Isabell and Tempel, Laura and Gruen, Katja and Heiß, Judith and Gutte, Clara and Matasci, Mattia and Schrepper, Andrea and Bauer, Reinhard and Berndt, Alexander and Jung, Christian and Schulze, P Christian and Neri, Dario and Franz, Marcus},
title = {Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody},
journal = {Cardiovascular Research},
year = {2024},
doi = {10.1093/cvr/cvae146}
}
EUVIMED